Stockscreener 앱 받기
5.20
7.22%
0.35
시장 영업 전:
5.17
-0.03
-0.58%
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Price to sales forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Enterprise value to revenue forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc. (FHTX) Cash Flow - TradingKey
FHTX|Foghorn Therapeutics Inc.|Price:4.850|Chg%:-0.220 - TradingKey
TradingKey - TradingKey
(FHTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
FHTXFoghorn Therapeutics Inc Options - Finviz
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate - Moomoo
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.
Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Foghorn Therapeutics (FHTX) Rises 4.71% as Biotech Stock Tests Key Resistance at $4.43Daily Profile - dars.gov.et
Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings - Barchart.com
Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX) - TradingView
Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
FHTX Forecast — Price Target — Prediction for 2027 - TradingView
Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike - Stock Titan
Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares - Stock Titan
Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant - Stock Titan
Director Michael Mendelsohn gets 28,000 Foghorn (FHTX) stock options at $4.08 - Stock Titan
Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options - Stock Titan
Director Douglas G. Cole receives 28,000 Foghorn (NASDAQ: FHTX) stock options - Stock Titan
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor - Stock Titan
Foghorn Therapeutics (FHTX) Edges Higher as Stock Holds Above Key SupportLow Volatility Picks - dars.gov.et
Foghorn Therapeutics Inc. (FHTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics Inc. (FHTX) Institutional Confidence - TradingKey
Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Foghorn Therapeutics Inc. (FHTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Foghorn Therapeutics (FHTX): Biotech Stock Gains 2.58% as Trading Momentum BuildsMid Cap Momentum - dars.gov.et
Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Investing News Network
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO) - The Globe and Mail
Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Foghorn Therapeutics to Present at Three Investor Conferences in May - geneonline.com
Foghorn Therapeutics (FHTX) Rises 1.44% as Biotech Stock Tests Key Resistance at $4.43MESA MA - newsline.com
Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
1.97%
0.83%
자본화:
|
볼륨(24시간):